41 completed. 41 Phase 2, 13 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 41 | Completed 41 |
| Phase 1 | 13 | Completed 13 |
| Phase 3 | 2 | Completed 2 |
Follow TMZ: new trials by email Literature Review of TMZ trials Research Report on TMZ
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma TMZ, ipilimumab 3mg/kg, Nivolumab - Glioblastoma, Gliosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2021-12-08 | 2026-04-17 |
| Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab - Gliosarcoma, MGMT-Unmethylated Glioblastoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 159 | 2020-09-01 | 2026-11-10 |
| 18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging - Glioblastoma, Malignant Glioma | Phase 2 | Completed | Mayo Clinic | 43 | 2019-03-28 | 2025-07-03 |
| Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma MN-166, Temozolomide - Glioblastoma, Recurrent Glioblastoma | Phase 1 / Phase 2 | Completed | MediciNova | 64 | 2018-12-29 | 2025-05-21 |
| Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 BMX-001, Radiation Therapy, Temozolomide - High Grade Glioma, Astrocytoma, Grade III | Phase 1 / Phase 2 | Completed | BioMimetix JV, LLC | 177 | 2018-09-25 | 2025-06-08 |
| Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma Dose-Escalated Radiation Therapy, Spectroscopic Magnetic Resonance Imaging, Temozolomide - Glioblastoma, Gliosarcoma | Phase 2 | Completed | Emory University | 30 | 2017-09-20 | 2025-08-03 |
| A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma Pamiparib, TMZ, Radiation - Brain and Central Nervous System Tumors | Phase 1 / Phase 2 | Completed | BeiGene USA, Inc. | 116 | 2017-07-24 | 2025-02-04 |
| Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis, Temozolomide - Cytomegalovirus Positive, Glioblastoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 65 | 2016-06-01 | 2023-06-18 |
| DC Migration Study for Newly-Diagnosed GBM Unpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs - Glioblastoma, Astrocytoma, Grade IV | Phase 2 | Completed | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | 64 | 2015-10-12 | 2023-06-08 |
| Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma LY2228820, Temozolomide, radiotherapy - Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Centre Jean Perrin | 18 | 2015-06-08 | 2019-08-14 |
| Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas Depatuxizumab mafodotin, Temozolomide, Lomustine - Glioblastoma | Phase 2 | Completed | AbbVie | 266 | 2015-02-17 | 2020-05-22 |
| Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma radiation therapy, temozolomide, plerixafor - Adult Ependymoblastoma, Adult Giant Cell Glioblastoma | Phase 1 / Phase 2 | Completed | Lawrence Recht | 30 | 2014-11-01 | 2018-10-23 |
| Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - Adult Solid Neoplasm, Childhood Solid Neoplasm | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2014-05-16 | 2021-03-26 |
| MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations Adavosertib, Carboplatin, Everolimus - Advanced Malignant Solid Neoplasm | Phase 2 | Completed | National Cancer Institute (NCI) | 208 | 2014-01-07 | 2023-09-29 |
| Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Cabozantinib S-malate, Dacarbazine, Laboratory Biomarker Analysis - Recurrent Uveal Melanoma, Stage III Uveal Melanoma AJCC v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2013-07-31 | 2022-08-04 |
| A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma PLX3397, Radiation Therapy, Temozolomide - Patients With Newly Diagnosed Glioblastoma | Phase 1 / Phase 2 | Completed | Daiichi Sankyo | 65 | 2013-07-18 | 2020-06-30 |
| A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) LDE225, TMZ - Medulloblastoma | Phase 2 | Completed | Novartis Pharmaceuticals | 22 | 2013-05-06 | 2017-08-11 |
| Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML) Temozolomide, Vorinostat - Acute Myeloid Leukemia With 11q23-abnormality in Relapse | Phase 2 | Completed | Steven E. Coutre | 23 | 2013-05-01 | 2018-08-09 |
| Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Dinutuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis - Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 73 | 2013-02-12 | 2022-10-24 |
| Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Capecitabine, Temozolomide, Bevacizumab - Gastrinoma, Glucagonoma | Phase 2 | Completed | Shaheen Shagufta | 20 | 2012-12-01 | 2024-02-06 |
Showing 20 of 41. Sign in to see all of them.
Glioblastoma (23) · Gliosarcoma (14) · Brain Neoplasms (9) · Glioma (6) · Astrocytoma (5) · Central Nervous System Neoplasms (5) · Melanoma (4) · Medulloblastoma (3) · Neoplasms (3) · Carcinoma, Islet Cell (2) · Neuroectodermal Tumors, Primitive (2) · Neuroectodermal Tumors, Primitive, Peripheral (2) · Pinealoma (2) · Skin Neoplasms (2) · Spinal Cord Neoplasms (2)
National Cancer Institute (NCI) (13) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · AbbVie (1) · BeiGene USA, Inc. (1) · BioMimetix JV, LLC (1) · Boehringer Ingelheim (1) · Centre Jean Perrin (1) · Children's Oncology Group (1) · Chinese Academy of Medical Sciences (1) · Daiichi Sankyo (1) · Emory University (1) · Hussein Tawbi (1) · Isarna Therapeutics GmbH (1) · John Sampson (1)
United States (38) · Canada (7) · Australia (5) · France (4) · Germany (3) · Netherlands (3) · Switzerland (3) · Austria (2) · Italy (2) · New Zealand (2) · Puerto Rico (2) · Russia (2) · Spain (2) · United Kingdom (2) · Belgium (1)
A P Chen (1) · Adam S Levy (1) · Andrew B Lassman (1) · Andrew Beelen, MD (1) · Charles Conrad, MD (1) · Dina Randazzo, DO (1) · Eric S Schafer (1) · Evanthia Galanis (1) · Gordana Vlahovic, MD (1) · Halla Nimeiri (1) · Hui-Kuo Shu, MD, PhD (1) · Hussein Tawbi, MD (1)
PMID 18775433, PMID 18955445, PMID 20725730, PMID 20921459, PMID 21149254, PMID 22517399, PMID 24101040, PMID 24552317, PMID 24991840, PMID 26602013, PMID 27098749, PMID 28039367, PMID 28549783, PMID 29077941, PMID 29982805, PMID 30854456, PMID 30996008, PMID 31386061, PMID 31724813, PMID 31747009, PMID 31795071, PMID 32343642, PMID 32548285, PMID 32652442, PMID 32691060, PMID 33170593, PMID 33601293, PMID 34417675, PMID 36822669, PMID 37218946, PMID 39571596, PMID 40779733, PMID 41544350
U10CA098543 (4), U10CA180886 (3), U01CA062475 (2), U10CA025224 (2), U10CA031946 (2), U10CA180821 (2), U10CA180868 (2), 2014 (1), 2017 (1), P30CA124435 (1), P30CA138292 (1), P50NS020023 (1), R01CA214557 (1), U10CA021661 (1), UM1CA097452 (1)